The present Invention relates to a Therapeutic Agent of Hunter Syndrome and, More specifically,A Therapeutic Agent of Hunter Syndrome that can reduce the number of Hospital visits of patients with Hunter Syndrome to twice a month or less,Containing a First composition for injected intravenously and a Second composition for injected subcutaneously.It presents a medicinal effect equivalent to or greater than that of a conventional intravenous injection once a week,Patients increase the compliance of taking Medicine and therapeutic agents in comparison with the Conventional Methods of treatment.And allows Greater comfort and convenience for the patient.According to the present Invention,The Method of co injection by IV / SC shows an equivalent or superior therapeutic effect compared with a conventional IV Injection, once a weekWhile allowing a patient to the hospital to visit less often than once a week, as in conventional visits,Replacing the conventional method of IV injection once a week, which requires the patient to visit the hospital once a week,By SC injections through which a caregiver of the patient can be performed directly in a Predetermined amount of intravenous injections.This goes against the conventional concept that the therapeutic effect made by SC injection would not be higher than the therapeutic effect achieved by IV injection.Therefore,The present Invention relates to a Therapeutic Agent and a method of treatment which dramatically improves the effect of treatment of Hunter Syndrome with respect to a TechnologyConventional Power.La presente invención se refiere a un agente terapéutico del síndrome de Hunter y, más específicamente, a un agente terapéutico del síndrome de Hunter que puede reducir el número de visitas al hospital de pacientes con síndrome de Hunter a dos veces al mes o menos, al contener una primera composición para inyectarse por vía intravenosa y una segunda composición para inyectarse por vía subcutánea, que presenta un efecto med
